OPPM

Opus Point Partners Management Portfolio holdings

AUM $46.9M
This Quarter Return
+16.56%
1 Year Return
-4.17%
3 Year Return
+83.22%
5 Year Return
+175.29%
10 Year Return
AUM
$126M
AUM Growth
+$126M
Cap. Flow
+$6.07M
Cap. Flow %
4.81%
Top 10 Hldgs %
42.55%
Holding
65
New
10
Increased
31
Reduced
2
Closed
1
Name Market Value Portfolio Weight Shares or Principal Shares
Change %
Capital Flow
AKBA icon
51
Akebia Therapeutics
AKBA
$833M
$387K 0.29% +42,019 New +$387K
TECH icon
52
Bio-Techne
TECH
$8.5B
$385K 0.29% 3,790 +1,323 +54% +$134K
ACAD icon
53
Acadia Pharmaceuticals
ACAD
$4.38B
$383K 0.28% 11,130 +1,088 +11% +$37.4K
AVXS
54
DELISTED
AveXis, Inc. Common Stock
AVXS
$380K 0.28% 5,000
ICPT
55
DELISTED
Intercept Pharmaceuticals, Inc.
ICPT
$375K 0.28% 3,312 +1,177 +55% +$133K
UTHR icon
56
United Therapeutics
UTHR
$13.8B
$373K 0.28% 2,756 +805 +41% +$109K
ALDR
57
DELISTED
Alder Biopharmaceuticals, Inc.
ALDR
$371K 0.28% +17,858 New +$371K
SCYX icon
58
SCYNEXIS
SCYX
$34.9M
$368K 0.27% +133,216 New +$368K
PGEN icon
59
Precigen
PGEN
$1.34B
$365K 0.27% 18,411 +8,536 +86% +$169K
BIVV
60
DELISTED
Bioverativ Inc. Common Stock
BIVV
$304K 0.23% +5,587 New +$304K
SIOX
61
DELISTED
Sio Gene Therapies Inc. Common Stock
SIOX
$260K 0.19% +17,425 New +$260K
STML
62
DELISTED
Stemline Therapeutics, Inc.
STML
$176K 0.13% +20,595 New +$176K
MCRB icon
63
Seres Therapeutics
MCRB
$166M
$158K 0.12% 14,000
LLY icon
64
Eli Lilly
LLY
$657B
0
QGENF
65
DELISTED
QIAGEN NV
QGENF
-111,683 Closed -$3.13M